Abstract
Triptan medications are selective serotonin receptor (5-HT1B/D) agonists approved for the treatment of acute migraine attacks. Among the currently available triptans, frovatriptan is unique with a long half-life (~26 h), metabolism by multiple pathways and a low side-effect profile. Clinical trial data demonstrates efficacy for frovatriptan across multiple doses, with the 2.5 mg dose selected for lower side effects. Frovatriptan is approved for use in the conventional treatment of an ongoing migraine attack, as are the other currently available triptan medications. The long half-life of frovatriptan has led to the initiation of studies of frovatriptan for the short-term prevention of menstrually related migraine attacks, during which patients are often difficult to treat. This newly investigated treatment approach for patients with predictable menstrually related migraine may, in the future, lead to treatment paradigms that benefit those patients with migraine attacks that are difficult to manage.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
